AbbVie Prices $10B Debt Offering to Fund Apogee Acquisition, Finalizing Coupons and Terms

summarizeSummary

AbbVie priced a $10 billion, nine-part bond deal to fund its Apogee Therapeutics acquisition, with final coupons from SOFR+42bps to 6.100% and a special mandatory redemption feature on shorter maturities if the deal collapses.

check_boxKey Events · Financing and Capital Events · ABBV

• $10B Debt Offering Priced

  AbbVie priced $10 billion in senior notes across nine tranches, with maturities from 2028 to 2066. Coupons range from SOFR+42bps (floating rate) to 6.100% (2066 notes), with yields modestly above benchmark Treasuries.

• Special Mandatory Redemption

  The first seven tranches (Floating Rate through 2038 Notes) carry a special mandatory redemption at 101% of principal if the Apogee acquisition is terminated. The 2056 and 2066 notes are not subject to this feature.

• Acquisition Financing

  Proceeds will fund the pending $10.9 billion acquisition of Apogee Therapeutics, announced June 22, 2026. The debt offering is a key step in closing that deal.

• Settlement and Timeline

  The notes are expected to settle on August 18, 2026 (T+10). The Apogee acquisition remains subject to customary closing conditions.

auto_awesomeAnalysis · ABBV · Life Sciences

AbbVie locked in pricing on a $10 billion, nine-tranche senior notes offering to finance its $10.9 billion acquisition of Apogee Therapeutics. The final terms reveal coupons ranging from SOFR+42bps on floating-rate notes to 6.100% on 40-year bonds, with yields modestly above benchmark Treasuries. A special mandatory redemption feature protects investors in the first seven tranches: if the Apogee deal falls through, those notes must be redeemed at 101% of principal. The long-dated 2056 and 2066 notes carry no such protection, reflecting their role as permanent capital. This pricing follows the preliminary prospectus filed yesterday and confirms strong demand across the maturity spectrum, with the deal expected to settle August 18.